11 articles with Oncopeptides AB
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
Data From Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting
Oncopeptides AB announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company's novel candidate melflufen, a peptide-conjugated alkylator belonging to the novel class of peptidase enhanced compounds, have been selected as poster presentations at the 2019 American Association for Cancer Research Annual Meeting on 29 March – 3 April 2019 in Atlanta, Georgia, USA.
Oncopeptides to present at the Cowen and Company Annual Healthcare Conference on Monday 11th March at 4:10 pm Eastern Standard Time
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Jakob Lindberg, CEO at Oncopeptides, will present the company at Cowen and Company 39th Annual Healthcare Conference in Boston on March 11th at 4:10 pm Eastern Standard Time, the presentation will be webcasted.
At the company's Capital Markets Day in December, an updated strategy for Oncopeptides' business was presented
Oncopeptides Will Host a Webcast in Conjunction With its Year-end Report 2018 on 22 February at 14.00 (CET)
Oncopeptides AB announces that the Company will release its Year-end Report on 22 February at 8:00 am CET.
Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the abstracts for the 60th American Society of Hematology (ASH) meeting (December 1st-4th, San Diego, California) have been released and include two melflufen presentations – one oral presentation (HORIZON) and one poster (ANCHOR)
Oncopeptides to Present New Data from Two Ongoing Trials ANCHOR and HORIZON in Patients with Relapsed/Refractory Multiple Myeloma at American Society of Hematology Annual Meeting
Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company currently focused on developing novel treatments for multiple myeloma, announced today that the abstracts for the 60th American Society of Hematology (ASH) Annual Meeting (December 1-4, San Diego, California) have been released and include two melflufen presentations – one oral presentation (HORIZON) and one poster (ANCHOR).
Oncopeptides AB Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
Oncopeptides AB Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients